

201 South Grand Avenue East
Springfield, Illinois 62763-0002

Telephone: (877) 782-5565
TTY: (800) 526-5812

Drug Utilization Review Board Meeting Summary September 15, 2022

The Drug Utilization Review (DUR) Board met on Thursday, September 15, 2022 at 8:30 a.m. via Web-ex for all attendees.

DUR Board members in attendance: Christopher Schriever, PharmD, Chairperson; Radhika Sreedhar, MD, Vice-chairperson; Sam An, PharmD.

Illinois Department of Healthcare and Family Services (HFS) Representatives: Jen DeWitt, BSPHarm, HFS Bureau of Professional and Ancillary Services (BPAS); Donna Clay, BSPHarm, Prior Authorization, University of Illinois Chicago (UIC); Jose Jimenez, Bureau Chief, BPAS; Arvind K. Goyal, MD, Medical Director, Medical Programs, HFS; Mary Lynn Moody, BSPHarm, UIC; Christina Petrykiw, PharmD, CDCES, UIC; Jonathan Samardzich, PharmD, UIC; Maurice Shaw, PharmD, BPAS.

Guests: Mariah Anbar, UIC; Sandra Arnold; Kenneth Berry, Alkermes; Kimbra Brooks, Abbot; Libby Burnsvold, Vertex; Jenny Carrell, Johnson & Johnson; Sarah Gao, AstraZeneca; Kelly Hamilton, Takeda; Sakib Hassan, Abbvie; Doug Johnson, Sobi; Robert Kilo, Biogen; Julie Lair, PTC Therapeutics; Dan Murphy, Abbvie; Heather Pezewski, Neurocrine; Francine Reis, Embecta; Cynthia VanSteenburg, Molina; Brooke Wilkins, Novartis; Shauna Williams, Bayer; Kim Witte, Krystal Biotech; Robert Wright, Indivior.

Call to order. Web event started at 8:30 am. Meeting was not started formally because there was no quorum of DUR Board members. Drs Stevens and Nikocecic had notified that they will not be able to attend. Call ended approximately at 9:50 am.

Meeting summary prepared by Christina A. Petrykiw, PharmD, CDCES.

Approved November 17, 2022 by the Illinois Drug Utilization Review Board.